SG10201912431XA - Vaccine constructs and uses thereof against staphylococcus infections - Google Patents

Vaccine constructs and uses thereof against staphylococcus infections

Info

Publication number
SG10201912431XA
SG10201912431XA SG10201912431XA SG10201912431XA SG10201912431XA SG 10201912431X A SG10201912431X A SG 10201912431XA SG 10201912431X A SG10201912431X A SG 10201912431XA SG 10201912431X A SG10201912431X A SG 10201912431XA SG 10201912431X A SG10201912431X A SG 10201912431XA
Authority
SG
Singapore
Prior art keywords
against staphylococcus
vaccine constructs
staphylococcus infections
infections
vaccine
Prior art date
Application number
SG10201912431XA
Inventor
François Malouin
Céline Ster
Julie Côté-Gravel
Éric Brouillette
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of SG10201912431XA publication Critical patent/SG10201912431XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG10201912431XA 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections SG10201912431XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
SG10201912431XA true SG10201912431XA (en) 2020-02-27

Family

ID=62018642

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901483QA SG11201901483QA (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections
SG10201912431XA SG10201912431XA (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201901483QA SG11201901483QA (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Country Status (24)

Country Link
US (2) US11324815B2 (en)
EP (1) EP3529260A4 (en)
JP (2) JP7181208B2 (en)
KR (1) KR20190082229A (en)
CN (1) CN109843910A (en)
AR (1) AR109847A1 (en)
AU (2) AU2017346974B2 (en)
BR (1) BR112019007796A2 (en)
CA (1) CA3037070A1 (en)
CL (1) CL2019001048A1 (en)
CO (1) CO2019005169A2 (en)
CR (1) CR20190249A (en)
DO (1) DOP2019000102A (en)
IL (1) IL265869A (en)
MX (2) MX2019004539A (en)
MY (1) MY195369A (en)
NZ (1) NZ751880A (en)
PE (1) PE20191320A1 (en)
PH (1) PH12019500843A1 (en)
RU (2) RU2022100889A (en)
SG (2) SG11201901483QA (en)
TW (1) TW201819402A (en)
UY (1) UY37448A (en)
WO (1) WO2018072031A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187702B1 (en) 1985-01-07 1990-03-14 Syntex (U.S.A.) Inc. N-(omega,omega-1-dialkoxy)- and n-(omega,omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1565478B1 (en) 2002-11-12 2017-08-02 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN1569893A (en) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 Antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope and use thereof
RU2419628C2 (en) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Immunogenic composition for use in vaccination against staphylococci
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
KR100729954B1 (en) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Formulation of SEC1 Mutated Protein and Method for Formulation of the Same
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9932373B2 (en) 2009-03-23 2018-04-03 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
CA2792956C (en) 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
US9091689B2 (en) 2011-06-19 2015-07-28 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
AU2022204585A1 (en) 2022-07-21
CA3037070A1 (en) 2018-04-26
AU2017346974A1 (en) 2019-03-14
RU2019115303A3 (en) 2021-03-02
JP2019531100A (en) 2019-10-31
AU2017346974B2 (en) 2022-03-31
RU2019115303A (en) 2020-11-23
US20190216913A1 (en) 2019-07-18
BR112019007796A2 (en) 2019-09-03
RU2022100889A (en) 2022-04-06
CL2019001048A1 (en) 2019-08-30
AR109847A1 (en) 2019-01-30
EP3529260A4 (en) 2020-12-16
PH12019500843A1 (en) 2019-12-02
MX2023001219A (en) 2023-03-03
KR20190082229A (en) 2019-07-09
RU2766354C2 (en) 2022-03-15
CO2019005169A2 (en) 2019-08-09
EP3529260A1 (en) 2019-08-28
DOP2019000102A (en) 2019-07-15
US11324815B2 (en) 2022-05-10
CR20190249A (en) 2019-10-16
JP2023025066A (en) 2023-02-21
UY37448A (en) 2018-03-23
IL265869A (en) 2019-06-30
MX2019004539A (en) 2019-06-12
JP7181208B2 (en) 2022-11-30
MY195369A (en) 2023-01-16
PE20191320A1 (en) 2019-09-24
TW201819402A (en) 2018-06-01
US20220288183A1 (en) 2022-09-15
SG11201901483QA (en) 2019-03-28
CN109843910A (en) 2019-06-04
NZ751880A (en) 2023-04-28
WO2018072031A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
ZA201607627B (en) Vaccine composition against streptococcus suis infection
IL250331B (en) Flagellin-based agents and uses including effective vaccination
IL247669A0 (en) Sixteen-membered macrolide compound and applications thereof
IL287825A (en) Sirp-alpha variant constructs and uses thereof
EP3273989A4 (en) Streptococcal vaccine
ZA201801172B (en) Mycoplasma vaccines and uses thereof
HK1231376A1 (en) Topical formulations and uses thereof
IL267278B (en) Insect elimination system and use thereof
HK1253725A1 (en) Novel antimicrobial peptide and use thereof
GB201721582D0 (en) S aureus antigens and immunogenic compositions
GB201616904D0 (en) Vaccine
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL250175A0 (en) Koc1-derived peptide and vaccine including same
IL258700A (en) Adjuvant and vaccine composition containing the same
IL265869A (en) Vaccine constructs and uses thereof against staphylococcus infections
PT3297666T (en) Molecular adjuvant and vaccine
SG11201607744XA (en) Antimicrobial air sanitizer compositions and their use
HK1247934A1 (en) Aml antigens and uses thereof
GB201712904D0 (en) Vaccine
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine
AU2016902014A0 (en) Vaccine
GB201603029D0 (en) Vaccine
AU2015901098A0 (en) Streptococcal vaccine
GB201403903D0 (en) Vesicular formulations and uses thereof